Entity
  • OKYO Pharma

    Created in 2018
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    867
  • Activities

  • Technologies

  • Entity types

  • Location

    55 Park Ln, London W1K 1PZ, UK

    London

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 8

  • Engaged corporates

    2
    0 0
  • Added in Motherbase

    1 year, 1 month ago
Description
  • Value proposition

    OKYO focuses on novel GPCR based therapeutics for eye diseases of unmet need and non-opioid analgesics for chronic pain.

    OKYO Pharma focuses on:
    A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis.
    An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.

Corporate interactions BETA
Corporate TypeTweets Articles
Novartis
Novartis
Pharmaceutical, Pharmaceutical Manufacturing
Novartis
Pharmaceutical, Pharmaceutical Manufacturing
Other

30 Jun 2023


Nasdaq
Nasdaq
Finance, Financial Services
Nasdaq
Finance, Financial Services
Other

31 Aug 2023


Similar entities
Loading...
Loading...
Social network dynamics